Abstract
Background Therapy resistance in pancreatic ductal adenocarcinoma (PDAC) is facilitated by the desmoplastic tumor microenvironment (TME) orchestrated by cancer associated fibroblasts (CAFs). Upon activation, pancreatic stellate cells (PSCs) deplete their intracellular retinoic acid (RA)-containing lipid droplets and secrete stromal remodeling proteins like pentraxin 3 (PTX3), leading to cancer progression. Preclinical evidence indicates that all-trans RA (ATRA) reprograms the TME, while circulating vitamin A and PTX3 were proposed as biomarkers for ATRA response in PDAC. To support further clinical development of RA-based therapies in PDAC, we studied the effects of ATRA on CAFs and patient-derived organoids (PDO) and evaluated the clinical relevance of these biomarkers in PDAC patients.
Methods We employed viability assays in human and murine organoid mono-and co-culture models to explore the efficacy of adding ATRA to gemcitabine (GEM). In parallel, we conducted a prospective observational study and assessed vitamin A and PTX3 as response biomarkers in peripheral blood collected before first treatment and at cycles 2 and 4 of treatment among patients with advanced PDAC receiving GEM with or without nab-paclitaxel (NAB-P).
Results In PDO monocultures, a significant additive effect of ATRA in combination with GEM on viability was observed in 5 (41%) of 12 PDOs and this effect was numerically more frequent in organoids from patients who had clinically responded to GEM. In human and murine 3D PDO+PSC/CAF co-cultures, ATRA demonstrated an additional direct impact on the viability of stromal cells. Clinically, among 18 patients with PDAC treated with GEM+/-NAB-P, patients with no treatment response (n=10) showed an increase in PTX3 and concomitant decrease in vitamin A levels under therapy. In contrast, response was associated with stable vitamin A levels and a trend towards lower PTX3 levels during chemotherapy.
Conclusions Our preclinical data support the repurposing of ATRA, an agent with favorable toxicity profile, to potentiate the efficacy of GEM in PDAC treatment. Complementing these results, our clinical data suggest vitamin A and PTX3 as promising response biomarkers in PDAC treatment, not restricted to ATRA containing regimens.
Competing Interest Statement
H.B.: honoraria from AbbVie, BMS, GSK, Lilly, MSD, Novartis, Pierre Fabre Pharma and Servier. D.A.R.: honoraria from CANTREAT. The remaining authors declare that they have no competing interests.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committee of the University of Freiburg gave ethical approval for this work (approval numbers 23-1226-S1 and 126/17). All patients provided written informed consent for collection and use of data and specimens.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
List of abbreviations
- APL
- acute promyelocytic leukemia
- ATRA
- all-trans retinoic acid
- BMI
- body mass index
- CAFs
- cancer-associated fibroblasts
- CDA
- cytidine deaminase
- CEMT
- Center for Experimental Models and Transgenic Services
- cfDNA
- cell-free DNA
- CRP
- C-reactive protein
- CT
- computed tomography
- ctDNA
- circulating tumor DNA
- DCK
- deoxycytidine kinase
- ddPCR
- digital droplet polymerase chain reaction
- DNMT1
- DNA methyltransferase 1
- ECM
- extracellular matrix
- ELISA
- enzyme-linked immunosorbent assay Fig. Figure
- FREEZE
- FREiburg und MEdizinische Fakultät ZEntrum für Biobanking (Center for Biobanking, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Germany).
- GEM
- gemcitabine
- HMA
- hypomethylating agents
- HU
- Hounsfield units
- IMAT
- intramuscular adipose tissue
- LM
- liver metastasis
- MRI
- magnetic resonance imaging
- NAB-P
- nab-paclitaxel
- NGS
- next generation sequencing
- NLR
- neutrophil to lymphocyte ratio
- OFU
- organoid forming units
- OS
- overall survival
- PC
- peritoneal carcinosis
- PDAC
- pancreatic ductal adenocarcinoma
- PDOs
- patient-derived organoids
- PSCs
- pancreatic stellate cells
- PT
- primary tumor
- PTX3
- pentraxin 3
- RA
- retinoic acid
- RT
- room temperature
- SAT
- subcutaneous adipose tissue
- SD
- standard deviation
- SM
- skeletal muscle
- TAMs
- tumor-associated macrophages
- TME
- tumor microenvironment
- VAT
- visceral adipose tissue
